BR112015011294A8 - nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas - Google Patents

nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas Download PDF

Info

Publication number
BR112015011294A8
BR112015011294A8 BR112015011294A BR112015011294A BR112015011294A8 BR 112015011294 A8 BR112015011294 A8 BR 112015011294A8 BR 112015011294 A BR112015011294 A BR 112015011294A BR 112015011294 A BR112015011294 A BR 112015011294A BR 112015011294 A8 BR112015011294 A8 BR 112015011294A8
Authority
BR
Brazil
Prior art keywords
pentoxifylline
biodegradable
drug
human
loaded
Prior art date
Application number
BR112015011294A
Other languages
English (en)
Other versions
BR112015011294A2 (pt
Inventor
Hernández Kunstmann Alejandro
Aurelio Laurido Fuenzalida Claudio
Andrées Vilos Ortíz Cristian
Ernesto Constandil Córdova Luis
Velásquez Cumplido Luis
Soledad Ibarra Durán Paula
Pelissier Serrano Teresa
Original Assignee
Univ Santiago Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Santiago Chile filed Critical Univ Santiago Chile
Publication of BR112015011294A2 publication Critical patent/BR112015011294A2/pt
Publication of BR112015011294A8 publication Critical patent/BR112015011294A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco de uso humano pentoxifilina” a presente invenção descreve uma nova formulação farmacêutica compre-endendo nanopartículas poliméricas do polímero biodegradável e biocompatível poli (ácido láctico - ácido glicólico) (plga) carregado com o fármaco pentoxifilina, o mé-todo de síntese de nanopartículas de plga carregadas com pentoxifilina e o uso desta no tratamento eficaz para alívio da dor crónica e para a prevenção da dor cró-nica pela administração de uma dose única.
BR112015011294A 2012-11-16 2013-11-15 nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas BR112015011294A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2012003209A CL2012003209A1 (es) 2012-11-16 2012-11-16 Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
PCT/CL2013/000084 WO2014075203A1 (es) 2012-11-16 2013-11-15 Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina

Publications (2)

Publication Number Publication Date
BR112015011294A2 BR112015011294A2 (pt) 2017-07-11
BR112015011294A8 true BR112015011294A8 (pt) 2019-10-22

Family

ID=50730445

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011294A BR112015011294A8 (pt) 2012-11-16 2013-11-15 nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas

Country Status (5)

Country Link
US (1) US20150283095A1 (pt)
BR (1) BR112015011294A8 (pt)
CL (1) CL2012003209A1 (pt)
MX (1) MX2015006187A (pt)
WO (1) WO2014075203A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
WO2023056372A1 (en) * 2021-09-29 2023-04-06 Oncour Pharma, Inc. Negatively charged particles for the treatment of inflammation-related burn injuries
CN114870023A (zh) * 2022-05-12 2022-08-09 成都市第三人民医院 一种缓释的视神经保护药物纳米合成材料及其制备方法和应用
CN116585488B (zh) * 2023-05-08 2024-02-23 广东省第二人民医院（广东省卫生应急医院） 一种罗哌卡因纳米载药材料及其制备方法
CN116869968B (zh) * 2023-09-07 2023-11-24 四川大学 一种靶向大脑和脑胶质瘤的纳米粒及其合成方法、应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
JP2009534309A (ja) * 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
KR100853309B1 (ko) * 2006-11-01 2008-08-20 나재운 시프로플록사신이 담지된 폴리락타이드글리콜라이드공중합체의 서방출 및 생분해성 나노입자 및 그 제조방법
EP2616055A1 (en) * 2010-09-13 2013-07-24 Tenera Therapeutics, LLC Compositions for treating cancer treatment - related fatigue
CA2876139A1 (en) * 2012-06-07 2013-12-12 President And Fellows Of Harvard College Nanotherapeutics for drug targeting

Also Published As

Publication number Publication date
BR112015011294A2 (pt) 2017-07-11
WO2014075203A1 (es) 2014-05-22
CL2012003209A1 (es) 2013-04-19
MX2015006187A (es) 2015-08-10
WO2014075203A8 (es) 2014-07-17
US20150283095A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
CY1120964T1 (el) Ετερογενη εμφυτευσιμα προϊοντα για χορηγηση φαρμακων
Foley et al. A chitosan thermogel for delivery of ropivacaine in regional musculoskeletal anesthesia
BR112015011294A8 (pt) nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas
UA106593C2 (uk) Пристрій для пролонгованого введення ліків, який містить полімери на основі поліуретану, та спосіб його виготовлення
WO2009148777A3 (en) Implantable drug delivery devices having alternating hydrophilic and amphiphilic polymer layers
CY1122771T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
EP2392363A3 (en) Drug coated expandable devices
WO2012018446A3 (en) Anchor delivery system
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
NZ704011A (en) Abuse deterrent pharmaceutical compositions for controlled release
MX2014010913A (es) Composicion farmaceutica que comprende farmaco empagliflozina y antiobesidad.
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
BR112015011778A2 (pt) métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática
WO2014036556A3 (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
WO2015019304A3 (fr) Compositions à libération continue à base d'acide hyaluronique, et leurs applications thérapeutiques
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements